Top 50 Cell Line Development in Asia

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Jushu Biotech develops a high-throughput biosensing platform utilizing CRISPR-based genome editing and ultrahigh-throughput droplet microfluidics to optimize microbial and mammalian cell lines for various applications in health, biochemicals, and agriculture. The company addresses the inefficiencies in traditional cell engineering by enabling rapid iteration and selection of engineered cells, significantly enhancing production capabilities.

Artblood develops a cell-based system for the production of artificial blood, addressing the global shortage and adverse effects associated with traditional blood transfusions. The company also creates specialized red blood cells for antibody detection and therapeutic delivery, enhancing the safety and efficacy of transfusion-related treatments.

Addy Gene specializes in CRISPR-Cas gene editing technology, offering services such as gene knockout, point mutation, and cell line construction to enhance genetic modification processes. The company improves the efficiency and precision of gene editing, enabling advancements in biotechnology and therapeutic applications for research institutions and enterprises.

Proton Bio provides contract development and manufacturing organization (CDMO) services specializing in gene and cell therapy. The company focuses on producing high-quality therapeutic products to meet the growing demand for advanced treatments in genetic disorders and cancer.

The startup develops cell-based therapies utilizing patented induced pluripotent stem cell (iPSC) generation and endothelial cell differentiation technology to treat cardiovascular disease. This approach enables the regeneration of damaged heart tissue, improving recovery outcomes for patients suffering from cardiovascular conditions.

Hopstem is a pharmaceutical company specializing in the differentiation of human induced pluripotent stem cells (iPSCs) into neural cells, alongside cell banking and engineering services. This technology addresses the need for reliable and scalable sources of neural cells for research and therapeutic applications in neurodegenerative diseases.

Solaris Bio develops serum-free culture media and related solutions for cell manufacturing in regenerative medicine, utilizing proprietary AI technology to enhance the safety and efficacy of cell products while reducing costs. The startup addresses the need for chemically defined and animal origin-free media formulations that optimize cell growth and differentiation for various therapeutic applications.

ProFuse Technology specializes in muscle cell differentiation, fusion, and maturation through proprietary supplements and immortalized bovine muscle cell lines, enhancing the efficiency of cultivated meat production. Their solutions aim to increase yield, reduce production costs, and accelerate production cycles for life science and cultivated meat companies.

The startup develops immune cell preparations and application technologies specifically designed for cancer patients, enhancing the efficacy of immunotherapy treatments. By focusing on personalized medicine, the company aims to improve patient outcomes and quality of life through targeted therapeutic interventions.

iCamuno Biotherapeutics develops a cell therapy drug using induced pluripotent stem cells (iPSCs) and gene editing technologies to create effective and affordable treatments for cancer patients. The company focuses on somatic cell reprogramming and stem cell differentiation to provide universal access to safe cellular therapies that meet unmet clinical needs.

Dewcell Biotherapeutics develops synthetic platelets using biomimetic technology and stem cell-derived processes to create transfusable blood products. The company addresses the critical shortage of donor platelets by establishing a consistent and high-quality production system for these essential components of blood.

Reprogenix develops proprietary stem cell therapies targeting diabetes, utilizing advanced cell injection techniques to restore insulin production. Their lead product, RGB5088, is currently undergoing clinical trials, positioning the company at the forefront of cellular treatments for metabolic disorders.

HELP Therapeutics develops allogeneic off-the-shelf cell therapies using induced pluripotent stem cells (iPSCs) to treat degenerative diseases, particularly in the cardiovascular and nervous systems. Their focus on safe and effective cell products aims to improve patient outcomes in conditions like end-stage heart failure.

Overland Pharmaceuticals is focused on the global development of cell therapies to treat various diseases. The company addresses the need for effective and scalable treatment options by utilizing advanced cell engineering techniques to enhance therapeutic efficacy.

Immuneel Therapeutics is developing Chimeric Antigen Receptor T cell (CAR-T) therapies to provide affordable and accessible cell and gene treatments for cancer patients in India. The startup addresses the lack of advanced cancer therapies in the country, aiming to improve patient outcomes through personalized immunotherapy.

The startup develops cell therapies utilizing Natural Killer (NK) cells from the innate immune system to target and eliminate cancerous tumors and viral infections. This approach provides a direct method for patients to receive effective immune cell therapy aimed at curing various cancer diseases.

Gracell Biotechnologies develops CAR-T cell therapies using its FasTCAR platform for next-day manufacturing of younger, less exhausted CAR-T cells, and its TruUCART platform for off-the-shelf allogeneic therapies. The company aims to provide effective treatment options for patients with cancer and autoimmune diseases, addressing the limitations of conventional CAR-T therapies.

Xellsmart develops clinical-grade induced pluripotent stem cell (iPSC) therapies specifically targeting neurodegenerative diseases, such as Parkinson's disease, for which there are currently no effective treatments. Their approach focuses on providing scalable and cost-effective stem cell solutions to improve patient outcomes in these critical areas of healthcare.

The startup develops regenerative drugs and eye drops that utilize cultured human corneal endothelial cells combined with a ROCK inhibitor to treat Fuchs corneal endothelial dystrophy and bullous keratopathy. This approach addresses the unmet medical needs of patients suffering from corneal endothelial disorders by providing effective treatment options.

East Ocyon Bio develops advanced cell and gene therapies focused on oncology. The company specializes in engineering Chimeric Antigen Receptor Natural Killer (CAR-NK) cells for cancer treatment applications. This platform aims to provide novel immunotherapeutic options for patients with various malignancies.

Stem Bio develops stem cell therapies and anti-cancer drugs to treat various malignancies and regenerative conditions. The company focuses on harnessing the potential of stem cells to enhance treatment efficacy and improve patient outcomes in oncology.

This biotechnology company develops artificial platelets through human-derived stem cell-induced differentiation into megakaryocytes, utilizing biomimetic technology for mass production. Their solution addresses the critical shortage of blood-derived platelets, providing a reliable alternative for medical applications.

CHITOSE Group leverages biotechnology to create sustainable, bio-based alternatives across pharmaceuticals, food, chemicals, agriculture, and energy. They develop novel processes and products, such as bio-PET resin and microalgae-derived biofuels, to transition industries away from fossil fuels and towards a circular economy.

Celloid develops a specialized 3D cell culture medium that enables quality-controlled long-term cultivation of organoids for research and therapeutic applications. This technology ensures consistent and viable organoid growth, addressing the challenges of maintaining cell viability over extended periods.

MBD specializes in 3D cell culture platforms, providing advanced tools for precision medicine and drug development. Their Cellvitro® technology enables more accurate testing of drug efficacy and sensitivity, addressing the limitations of traditional 2D cell cultures in biomedical research.

BioTroy Therapeutics develops first-in-class biopharmaceuticals targeting cancer and immunological disorders through the discovery of novel ligands for CD3, enhancing T-cell activation in immunotherapy. Their approach aims to improve treatment efficacy and patient outcomes in oncology and immune-related conditions.

Microlysis utilizes artificial intelligence and machine learning to analyze thousands of videos of cell-cell interactions, enhancing the development of targeted cell therapies. This approach aims to improve the efficacy and precision of treatments for various medical conditions.

This biotech company is developing homologous gamma delta CAR-T cell therapy and biopharmaceutical production using animal cell lines to enhance immune responses in cancer patients. By strengthening immunity, the company aims to improve patient outcomes in the fight against cancer.

Hexaell Biotech develops cell therapies targeting severe liver diseases through advanced biopharmaceutical techniques. The company focuses on addressing the unmet medical needs of patients suffering from liver conditions by providing innovative treatment options that enhance liver function and improve patient outcomes.

The startup develops bovine serum products that comply with biological raw material standards by extracting blood from mature cattle to obtain essential factors for cell proliferation. This provides medical practitioners with high-quality serum specifically designed for bovine cell culture applications.

IPS Portal provides contract testing services for induced pluripotent stem (iPS) cells, facilitating research in drug development, regenerative medicine, and cosmetics. The company supports clients by evaluating the performance of cell culture systems and related devices, addressing the challenges of developing effective therapies and technologies in the life sciences sector.

The startup develops therapeutic cell technologies for regenerative medicine, specifically targeting musculoskeletal-related diseases through its proprietary cell therapy platform. This approach addresses the unmet medical need for effective treatments in patients suffering from tissue injuries in the musculoskeletal system.

The startup develops a stem cell therapy that utilizes organ-intrinsic stem cell separation technology to achieve high-purity cell separation without enzymatic disassembly of organ tissue. This approach aims to enhance regenerative treatment options for patients with intractable diseases by promoting self-replication of living cells.

Cymss-Bio manufactures the TASCL microplate, designed for the three-dimensional culture of spheroids, enabling the efficient production of uniform cell aggregates for regenerative medicine applications. The company also provides support services for medical facilities to implement PRP and stem cell therapies, addressing the regulatory and operational challenges associated with adopting these advanced treatments.

Biomonadic is an AI platform that utilizes reinforcement learning and IoT sensors to optimize cell culture bioprocesses for gene therapy production, specifically targeting Klotho anti-aging therapies. By integrating real-time data analysis with customized manufacturing protocols, the platform enhances quality, growth, and yield while reducing production costs.

Mellow Energy specializes in the development and production of large-area perovskite solar cells, achieving high efficiency and low production costs for both centralized and distributed photovoltaic systems. The company addresses the need for affordable and efficient solar energy solutions by offering flexible and versatile solar cell products suitable for various applications, including building-integrated photovoltaics and indoor energy harvesting.

Rege Nephro develops therapeutics specifically targeting renal diseases, focusing on improving the quality of life for patients suffering from these conditions. The company's research and development efforts aim to address the unmet medical needs in renal care through innovative treatment solutions.

SingCell offers outsourced contract research organization (CRO) services, including quality control testing and process development, specifically for stem cell therapy and clean meat production. The company addresses the need for reliable manufacturing and analytical capabilities in these emerging industries, ensuring compliance and efficiency in their production processes.

This food biotech company employs cellular agriculture to produce sustainable animal cell-based food ingredients, eliminating the need for traditional livestock farming. This approach significantly reduces greenhouse gas emissions and land use, contributing to enhanced food security.

The startup develops cell and antibody therapeutics for cancer treatment, focusing on immune cell therapy that enhances cancer cell recognition and therapeutic efficacy. This approach provides patients with more effective treatment options, improving healthcare outcomes in oncology.

The startup develops stem cell therapeutics utilizing primed stem cells and their exosomes, employing single-cell analysis for precise gene editing. This approach aims to provide effective treatments for incurable diseases by targeting and correcting the underlying genetic causes.

Zephyrm Biotech develops stem cell medications to address degenerative diseases and enhance regenerative therapies. By utilizing advanced stem cell technology, the company aims to improve patient outcomes and reduce the burden of chronic health conditions.

Biozipcode, Inc. is developing a therapeutic drug aimed at curing diabetes through cell-targeting technology that delivers medication directly to specific cells. This approach addresses the limitations of current treatments that only manage diabetes symptoms rather than providing a complete cure.

ThinkCyte utilizes VisionSort, a technology that combines fluorescence flow cytometry with high-dimensional morphological profiling and AI for label-free cell sorting and unbiased single-cell profiling. This approach enables rapid identification and selection of therapeutically relevant cells, enhancing efficiency in cell therapy research and drug discovery.

This company develops multi-modal Treg cell therapies targeting unmet medical needs in neurodegenerative, autoimmune, and metabolic diseases. They utilize proprietary platforms for the isolation, expansion, and clinical-grade production of regulatory T cells. Their focus is on delivering innovative cell therapies to treat conditions like ALS and various autoimmune disorders.

The startup develops therapeutics that specifically target cancer stem cells, utilizing stem cell-targeted delivery methods to enhance treatment efficacy. Their approach aims to reduce pain and improve the quality of life for cancer patients through translational research in drug development.

CART Medical develops proprietary immune cell therapies targeting solid tumors through advanced recognition and activation mechanisms. The company aims to enhance treatment efficacy and accelerate the clinical application of these therapies, addressing the limitations of current cancer treatments.

ImmunoACT develops NexCAR19, India's first indigenous CAR-T cell therapy, which modifies a patient's T-cells to enhance their ability to target and eliminate B-cell cancers such as Acute Lymphoblastic Leukemia and Large B-cell Lymphomas. This therapy addresses the high relapse rates and lack of response to first-line treatments, aiming to improve overall survival outcomes for patients with limited treatment options.

The startup is developing hydrogen production technology and Type 4 tanks for hydrogen storage, focusing on the research and development of high-temperature fuel cell manufacturing processes. This approach aims to enhance the efficiency and scalability of hydrogen fuel systems in aviation applications.